Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-297-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$858.29 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo Co. (NASDAQ:MASI) posted its quarterly earnings results on Wednesday, July, 31st. The medical equipment provider reported $0.76 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.73 by $0.03. The medical equipment provider had revenue of $229.60 million for the quarter, compared to analysts' expectations of $222.46 million. Masimo had a net margin of 22.15% and a return on equity of 17.82%. The business's revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 EPS. View Masimo's Earnings History.
When is Masimo's next earnings date?
What guidance has Masimo issued on next quarter's earnings?
Masimo issued an update on its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $3.15 for the period, compared to the Thomson Reuters consensus estimate of $3.12. The company issued revenue guidance of $926.3 million, compared to the consensus revenue estimate of $919.94 million.
What price target have analysts set for MASI?
5 analysts have issued 12 month price objectives for Masimo's stock. Their predictions range from $134.50 to $180.00. On average, they expect Masimo's share price to reach $160.50 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price. View Analyst Price Targets for Masimo.
What is the consensus analysts' recommendation for Masimo?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo.
What are Wall Street analysts saying about Masimo stock?
Here are some recent quotes from research analysts about Masimo stock:
- 1. According to Zacks Investment Research, "Masimo exited the first quarter on a robust note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter. Notably, the company’s non-invasive technology shipments surged in the quarter. Raised guidance for 2019 buoys optimism as well. Management is optimistic about Masimo’s recent initiative for hospital automation. The company recently launched its Iris Device Management System in the United States. Additionally, Masimo has launched Doctella to boost its remote care automation platform. Shares of Masimo outperformed the industry in a year’s time. Meanwhile, Masimo’s Royalty and Other segment witnessed significant softness in the quarter. In fact, management anticipates no meaningful contribution from the unit in 2019. Furthermore, Masimo expects foreign currency headwinds in 2019 to impact the top line. The company faces fierce competition from MedTech bigwigs." (5/8/2019)
- 2. Needham & Company LLC analysts commented, "We hosted investor meetings with Kammerman, this week in the Midwest. We come away from the meetings with a better appreciation of MASI’s growth and margin outlook. We believe that MASI’s business model and product portfolio should enable it to sustain strong and consistent top and bottom line growth. Additionally, we think that the impact of the Philips agreement should cumulatively build as boards with MASI’s Rainbow and other measurements are installed in an increasing portion of Philips’ installed base. And we see several catalysts (detailed below) that could help MASI shares in 2019. Given all of this, we reiterate our Buy rating." (2/1/2019)
Has Masimo been receiving favorable news coverage?
Press coverage about MASI stock has trended negative this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Masimo earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Masimo.
Are investors shorting Masimo?
Masimo saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 808,700 shares, an increase of 12.0% from the July 15th total of 721,800 shares. Based on an average trading volume of 407,100 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.7% of the company's stock are short sold. View Masimo's Current Options Chain.
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include SONOVA HLDG AG/ADR (SONVY), Varian Medical Systems (VAR), GETINGE AB/ADR (GNGBY), LivaNova (LIVN), CONMED (CNMD), Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Zynex (ZYXI) and Semler Scientific (SMLR).
What other stocks do shareholders of Masimo own?
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 54)
- Mr. Micah Young, Exec. VP of Fin. & CFO (Age 40)
- Mr. Anand Sampath, Chief Operating Officer (Age 53)
- Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 74)
- Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 46)
Who are Masimo's major shareholders?
Masimo's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.13%), BlackRock Inc. (13.13%), Vanguard Group Inc. (8.34%), Invesco Ltd. (2.32%), AQR Capital Management LLC (1.72%) and Bank of New York Mellon Corp (1.30%). Company insiders that own Masimo stock include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Institutional Ownership Trends for Masimo.
Which institutional investors are selling Masimo stock?
MASI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, D. E. Shaw & Co. Inc., Scout Investments Inc., First Trust Advisors LP, Renaissance Technologies LLC, BTIM Corp., Schroder Investment Management Group and Eaton Vance Management. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo.
Which institutional investors are buying Masimo stock?
MASI stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Handelsbanken Fonder AB, Janus Henderson Group PLC, Janus Henderson Group PLC, AQR Capital Management LLC, APG Asset Management N.V. and Natixis. View Insider Buying and Selling for Masimo.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $151.98.
How big of a company is Masimo?
Masimo has a market capitalization of $8.11 billion and generates $858.29 million in revenue each year. The medical equipment provider earns $193.54 million in net income (profit) each year or $3.03 on an earnings per share basis. Masimo employs 1,500 workers across the globe.View Additional Information About Masimo.
What is Masimo's official website?
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]
MarketBeat Community Rating for Masimo (NASDAQ MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
